116 related articles for article (PubMed ID: 37693441)
1. Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant
Romanowski EG; Mumper SM; Shanks HQ; Yates KA; Mandell JB; Zegans ME; Shanks RMQ
bioRxiv; 2023 Sep; ():. PubMed ID: 37693441
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant
Romanowski EG; Mumper SM; Shanks HQ; Yates KA; Mandell JB; Zegans ME; Shanks RMQ
Ophthalmol Sci; 2024; 4(4):100452. PubMed ID: 38560275
[TBL] [Abstract][Full Text] [Related]
3.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Lagacé-Wiens PRS; Schweizer F; Bay D; Lynch JP; Mulvey MR; Zhanel GG
Microbiol Spectr; 2022 Aug; 10(4):e0172422. PubMed ID: 35758747
[TBL] [Abstract][Full Text] [Related]
4. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
Fernandes M; Vira D; Medikonda R; Kumar N
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):315-22. PubMed ID: 26537122
[TBL] [Abstract][Full Text] [Related]
5.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
6. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
[TBL] [Abstract][Full Text] [Related]
7. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Khan M; Ma K; Wan I; Willcox MD
Cont Lens Anterior Eye; 2023 Jun; 46(3):101819. PubMed ID: 36732125
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
Mei JA; Johnson W; Kinn B; Laskey E; Nolin L; Bhamare P; Stalker C; Dunman PM; Wozniak RAF
Transl Vis Sci Technol; 2022 May; 11(5):26. PubMed ID: 35612831
[TBL] [Abstract][Full Text] [Related]
11. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
13. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol for treatment of an empyema due to extensively drug-resistant
Kufel WD; Steele JM; Riddell SW; Jones Z; Shakeraneh P; Endy TP
IDCases; 2020; 21():e00863. PubMed ID: 32577400
[TBL] [Abstract][Full Text] [Related]
15. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188
[TBL] [Abstract][Full Text] [Related]
17. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Kowalski RP; Romanowski EG; Mah FS; Shanks RM; Gordon YJ
Acta Ophthalmol; 2010 Jun; 88(4):e120-5. PubMed ID: 20456251
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Li SA; Liu J; Xiang Y; Wang YJ; Lee WH; Zhang Y
Antimicrob Agents Chemother; 2014 Jun; 58(6):3144-50. PubMed ID: 24637683
[TBL] [Abstract][Full Text] [Related]
19.
Malisova L; Vrbova I; Pomorska K; Jakubu V; Zemlickova H
Microb Drug Resist; 2023 Oct; 29(10):485-491. PubMed ID: 37610876
[TBL] [Abstract][Full Text] [Related]
20. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
